COMMUNIQUÉS West-GlobeNewswire
-
Lighthouse Autism Center Opening New Autism Therapy Center in Rocky Mount, North Carolina
31/03/2026 -
Trethera Announces Massachusetts General Hospital Clinical Trial Collaboration to Evaluate TRE-515 in ALS Patients
31/03/2026 -
Lumina Therapy Alliance Expands National Footprint with Addition of The Therapy Group of DC, Reaching Nearly 400 Clinicians Nationwide
31/03/2026 -
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
31/03/2026 -
Wildfire Smoke is Coming; Millions of Canadian Lungs Aren’t Ready
31/03/2026 -
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
31/03/2026 -
Mike Tyson and TerrAscend Expand TYSON 2.0 Footprint into Pennsylvania and Maryland
31/03/2026 -
Alabama Attorney General Steve Marshall Champions The Helios Alliance's Project RenewAL to Advance Statewide Opioid Abatement
31/03/2026 -
ZymoChem's BAYSE™ Becomes First Bio-Based Superabsorbent to Match and Outperform Petroleum-Based Materials
31/03/2026 -
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2025
31/03/2026 -
Global Medtech CDMO Market Grows to $96.5B in 2025 as Pharma-Medtech Convergence Emerges as a Defining Accelerator
31/03/2026 -
EssilorLuxottica and Meta Expand AI Glasses Portfolio with Ray-Ban Meta Optics Styles
31/03/2026 -
EssilorLuxottica et Meta élargissent leur portefeuille de lunettes IA avec les modèles Ray-Ban Meta optiques
31/03/2026 -
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
31/03/2026 -
Berry Street Joins Amazon's Health Benefits Connector, Expanding Access to one of Healthcare's Most Underutilized Benefits
31/03/2026 -
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
31/03/2026 -
Catheter Precision Reports 2025 Results and Updates on Strategic Expansion
31/03/2026 -
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
31/03/2026 -
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
31/03/2026
Pages